Background. The aim of this study was to assess plasma levels of endothelium- and heart-associated microRNAs
(miRNAs) miR-126 and miR-499, respectively, using quantitative reverse transcriptase polymerase chain reaction.
Methods: A two-step analysis was conducted on 75 patients undergoing off-pomp coronary artery bypass graft
(CABG) surgery. Five biomarkers of inflammation and cardiac injury were assessed in addition to the abovementioned
miRNAs.
Results. Plasma concentrations of miRNAs were found to be significantly correlated with plasma levels of cardiac
troponin I (cTnI) (miR-499, r 0.49, p~0.002; miR-126, r = 0.30, p~0.001), indicating cardiac damage. Data analysis
revealed that miR-499 had higher sensitivity and specificity for cardiac injury than miR-126, which reflects more
endothelial activation. Interestingly, a strong correlation was observed between both miRNAs and uric acid (UA)
levels with ventricular contractility measured as ejection fraction (EF) (miR-499/EF%, r = 0.58, p~0.004; UA/EF%,
r = -0.6, p~0.006; UA/miR-499, r = -0.34; UA/miR-126, r = 0.5, p~0.01).
Conclusions. In patients undergoing CABG, circulating miR-126/499 is associated with presentation of traditional
risk factors and reflects post-operative response to injury. Plasma pool of miRNAs likely reflects extracellular
miRNAs which are proportional to intracellular miRNA levels. Therefore, circulating levels of these miRNAs have
prognostic implications in detection of higher risk of future cardiovascular events.
CABG, Cardiac damage, miR-126, miR-499, Off-pomp, Uric acid
Financial support: No financial support has been received for this
study.
Fatemeh Pourrajab Department of Clinical Biochemistry and Molecular Biology School of Medicine Shahid Sadoughi University of Medical Sciences P.O. 8915173149, Yazd, Iran mkh7116@yahoo.com
We thank the nursing staff of the Afshar hospital, Shahid Sadoughi
University of Medical Sciences in Yazd, Iran, for assisting in data
collection.

Trending Topic
Cardiovascular medicine continues to advance at a remarkable pace, driven by innovation, interdisciplinary collaboration and an ever-deepening understanding of disease mechanisms. As patient populations age and chronic conditions become increasingly complex, the field stands at the intersection of precision therapy, digital health and preventive strategy. This winter issue of Heart International reflects that transformation, highlighting […]
Cardiovascular medicine continues to advance at a remarkable pace, driven by innovation, interdisciplinary collaboration and an ever-deepening understanding of disease mechanisms. As patient populations age and chronic conditions become increasingly complex, the field stands at the intersection of precision therapy, ...
Heart failure (HF) is a complex and progressive clinical syndrome that significantly impacts morbidity, mortality and quality of life (QoL).1 On a global scale, HF has become an escalating public health concern, affecting more than 64 million individuals in 2017, and this ...
Heart failure (HF) is a global health burden, with a 2019 prevalence of 711.90 per 100,000 population, totalling 56.19 million cases and 5.05 million years lived with disability, despite only modest declines since 1990.1Â Recent years have shown an uptick in prevalence, driven by ageing populations ...
Functional status refers to an individual’s ability to carry out different levels of activities to meet the needs of daily living.1 Patients with heart failure (HF) commonly have poor functional status that is affected by a number of physical, ...
Heart failure (HF), a prevalent disease, is the common final pathway of several conditions, which result in the activation of numerous neurohumoral pathways. Cardiorenal interaction plays an essential role in the progression of the disease, and the use of diuretics ...
Palliative care (PC) is recommended as a standard of practice for all patients with heart failure (HF) and is supported by evidence of improved patient outcomes (e.g. reduction in symptoms refractory to cardiovascular therapies and improved shared decision-making).1Â PC ...
Heart failure (HF) is a common clinical diagnosis often requiring hospitalization secondary to patient decompensation associated with clinically determined 'dry' or 'wet' volume states. However, fluid overload is the more common basis for clinical deterioration accounting for the majority of ...
Heart failure (HF) is a complex syndrome caused by a variety of cardiac and non-cardiac diseases, and is associated with high mortality and hospitalization rates.1Â Treatment has been traditionally based on a detailed history and physical examination. However, since cardiac ...
Conventionally, according to the European Society of Cardiology pacing and cardiac resynchronization therapy (CRT) guidelines, patients with clinical heart failure and an echocardiographically measured left ventricular (LV) ejection fraction of <35% are considered for CRT implantation or standard right ventricular (...
Atrial fibrillation (AF) and heart failure (HF) often co-exist. The incidence of AF is estimated to reach 45% of patients with HF and rises with the severity of HF symptoms, from about 5% of patients in the New York Heart Association (NYHA) ...
Heart failure (HF) is an increasingly prevalent clinical syndrome resulting from a variety of disease processes impeding the heart’s ability to effectively circulate blood. With advances in care and a steadily growing and aging population, HF management is becoming ...
Heart failure (HF) is a highly prevalent and morbid disease in the USA, imposing a significant burden on patients, hospitals and the health system. The prevalence of HF continues to increase, with over 650,000 new HF cases diagnosed annually.1Â There are ...
Keep track of your clinical interests and newsletter subscriptions.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Already registered? Login below.